<?xml version='1.0' encoding='utf-8'?>
<document id="30785057"><sentence text="Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction."><entity charOffset="0-9" id="DDI-PubMed.30785057.s1.e0" text="Dasatinib" /><entity charOffset="52-64" id="DDI-PubMed.30785057.s1.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.30785057.s1.e0" e2="DDI-PubMed.30785057.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s1.e0" e2="DDI-PubMed.30785057.s1.e1" /></sentence><sentence text="This study was designed to investigate the effects of dasatinib and nilotinib on the pharmacokinetics of cyclosporine in rats, as these drugs have been reported to be cytochrome P450 3A4 (CYP3A4) substrates"><entity charOffset="54-63" id="DDI-PubMed.30785057.s2.e0" text="dasatinib" /><entity charOffset="68-77" id="DDI-PubMed.30785057.s2.e1" text="nilotinib" /><entity charOffset="105-117" id="DDI-PubMed.30785057.s2.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.30785057.s2.e0" e2="DDI-PubMed.30785057.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s2.e0" e2="DDI-PubMed.30785057.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30785057.s2.e0" e2="DDI-PubMed.30785057.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30785057.s2.e1" e2="DDI-PubMed.30785057.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30785057.s2.e1" e2="DDI-PubMed.30785057.s2.e2" /></sentence><sentence text="" /><sentence text="Control and test groups (n = 5) were treated with vehicle and dasatinib (4 mg/kg, and 16 mg/kg, oral) or nilotinib (94 mg/kg, oral), respectively, for 8 consecutive days"><entity charOffset="62-71" id="DDI-PubMed.30785057.s4.e0" text="dasatinib" /><entity charOffset="105-114" id="DDI-PubMed.30785057.s4.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.30785057.s4.e0" e2="DDI-PubMed.30785057.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s4.e0" e2="DDI-PubMed.30785057.s4.e1" /></sentence><sentence text=" On day 8, all groups were administered cyclosporine (30 mg/kg) 1 h after the last dose of dasatinib or nilotinib"><entity charOffset="40-52" id="DDI-PubMed.30785057.s5.e0" text="cyclosporine" /><entity charOffset="91-100" id="DDI-PubMed.30785057.s5.e1" text="dasatinib" /><entity charOffset="104-113" id="DDI-PubMed.30785057.s5.e2" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.30785057.s5.e0" e2="DDI-PubMed.30785057.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s5.e0" e2="DDI-PubMed.30785057.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30785057.s5.e0" e2="DDI-PubMed.30785057.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30785057.s5.e1" e2="DDI-PubMed.30785057.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30785057.s5.e1" e2="DDI-PubMed.30785057.s5.e2" /></sentence><sentence text=" Blood was collected from the retro-orbital plexus in heparinized tubes at different time points (0, 0" /><sentence text="5, 1, 1" /><sentence text="5, 2, 3" /><sentence text="5, 8, 12, and 24 h)" /><sentence text=" The cyclosporine concentration in blood samples was determined by ultra-performance liquid chromatography-tandem mass spectrometry"><entity charOffset="5-17" id="DDI-PubMed.30785057.s10.e0" text="cyclosporine" /></sentence><sentence text=" The effects of dasatinib on CYP3A2 mRNA and protein expression levels were also investigated"><entity charOffset="16-25" id="DDI-PubMed.30785057.s11.e0" text="dasatinib" /></sentence><sentence text="" /><sentence text="Dasatinib significantly reduced the maximum blood concentration (Cmax) of cyclosporine by 85"><entity charOffset="0-9" id="DDI-PubMed.30785057.s13.e0" text="Dasatinib" /><entity charOffset="74-86" id="DDI-PubMed.30785057.s13.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.30785057.s13.e0" e2="DDI-PubMed.30785057.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s13.e0" e2="DDI-PubMed.30785057.s13.e1" /></sentence><sentence text="7%, and increased hepatic and intestinal CYP3A2 mRNA and protein expression levels by 2" /><sentence text="4- and 1" /><sentence text="25-fold, respectively, compared to those in the controls (p &lt;  0" /><sentence text="05)" /><sentence text=" On the other hand, nilotinib had no significant effects on cyclosporine pharmacokinetic parameters"><entity charOffset="20-29" id="DDI-PubMed.30785057.s18.e0" text="nilotinib" /><entity charOffset="60-72" id="DDI-PubMed.30785057.s18.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.30785057.s18.e0" e2="DDI-PubMed.30785057.s18.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s18.e0" e2="DDI-PubMed.30785057.s18.e1" /></sentence><sentence text="" /><sentence text="Dasatinib significantly reduced cyclosporine exposure, which was most probably related to the induction of CYP3A-mediated cyclosporine metabolism"><entity charOffset="0-9" id="DDI-PubMed.30785057.s20.e0" text="Dasatinib" /><entity charOffset="32-44" id="DDI-PubMed.30785057.s20.e1" text="cyclosporine" /><entity charOffset="122-134" id="DDI-PubMed.30785057.s20.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.30785057.s20.e0" e2="DDI-PubMed.30785057.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30785057.s20.e0" e2="DDI-PubMed.30785057.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30785057.s20.e0" e2="DDI-PubMed.30785057.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30785057.s20.e1" e2="DDI-PubMed.30785057.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30785057.s20.e1" e2="DDI-PubMed.30785057.s20.e2" /></sentence><sentence text="" /></document>